EPHORAN MULTI IMAGING SOLUTIONS

Taros Chemicals GmbH & Co. KG, an independent, privately owned contract research organization based in Dortmund, Germany, has been serving the chemistry needs of pharmaceutical, chemical and biotech companies since its inception in 1999. A forerunner in the early German biotech scene, Taros can claim more than 13,000 syntheses, research and process chemistry projects delivered to-date to an increasingly expanding and diverse base of global customers.

In its state-of-the-art facilities in Dortmund's prestigious BioMedizinZentrum (BMZ), the hub of top ranking biotech organizations, Taros'​ team of highly creative and skilled scientists, aided by its state-of-the-art laboratory facilities, are wholly committed to solving a wide range of customers'​ R&D problems in innovative drug discovery, medicinal chemistry and classical synthetic chemistry. Their collective knowledge and experience in industrial organic chemistry, span a period of over 160 years, and in active drug discovery, around 60 years, covering the full spectrum, from big pharma to biotechnology. Taros is active today in therapeutic areas which include oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious diseases, in all small-molecule target classes.

Our company's mission is to enhance the quality of human lives by providing advanced and innovative chemistry-driven technologies to our customers R&D endeavors in the global marketplace. We strive hard to provide creative, holistic and cost-effective solutions with the highest level of quality, reliability and integrity. We continuously endorse loyalty and commitment in our employees, inspiring them to provide exceptional value to our customers'​ R&D processes, by anticipating hurdles before they arise, by foreseeing potential cost and lead time reductions, and most importantly, by facilitating their competitive and "early to market"​ advantage.

Crown CRO is a privately owned Finnish CRO founded in 2005. Our headquarters are in Espoo, which is located in Finland’s capital city region. Crown CRO offices are located in Finland, Sweden, Denmark, Norway, Estonia, Latvia and Lithuania. We have ongoing trials managed by our employees in Netherlands, Belgium, UK, Iceland, Ukraine and Belarus. Rest of the Europe and USA we cover through our qualified CRO network.

Our services cover Phase I – IV clinical development from protocol design to final reporting or any parts of the trial in various business models. Data services, Regulatory consulting, Pharmacovigilance, QA, Study Rescue Services and Medical Translation services complete the service package.

Our key therapeutic areas include, but not limited to, CNS, Oncology, Endocrinology, Cardiovascular, Respiratory and Musculoskeletal. We also have strong recent experience in Medical Devices from various indications.

Our passion for research across all our in-house Full-Service functions provide effective and innovative solutions with seamless cooperation for Phase I-III trials in Europe offering special focus on Nordic-Baltic area, together with our own Global Data Services ensuring consistency regardless of where your trials are located, offer you unrivalled customer attention, flexibility and high local level expertise which are key assets you can count on.

See www.crowncro.com for more information.

Dokumeds is your guide through the clinical development journey towards the market, in Europe and beyond: transparent budgets, cost-effective solutions and accelerated timelines.

Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies.

In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 50,000 staff across a network of more than 900 independent companies in over 50 countries, operating more than 800 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing.

Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by 35% each year (in compound average) to over EUR 4.5 billion in 2019.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.